- Home
- ISPC vs REVB Comparison
ISPC vs REVB Comparison
Compare ISPC & REVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ISPC
- REVB
- Stock Information
- Founded
- ISPC 2009
- REVB 2020
- Country
- ISPC United States
- REVB United States
- Employees
- ISPC N/A
- REVB N/A
- Industry
- ISPC Precision Instruments
- REVB Biotechnology: Pharmaceutical Preparations
- Sector
- ISPC Health Care
- REVB Health Care
- Exchange
- ISPC Nasdaq
- REVB Nasdaq
- Market Cap
- ISPC 3.1M
- REVB 3.7M
- IPO Year
- ISPC 2021
- REVB N/A
- Fundamental
- Price
- ISPC $0.94
- REVB $0.79
- Analyst Decision
- ISPC
- REVB
- Analyst Count
- ISPC 0
- REVB 0
- Target Price
- ISPC N/A
- REVB N/A
- AVG Volume (30 Days)
- ISPC 51.4K
- REVB 3.0M
- Earning Date
- ISPC 08-05-2025
- REVB 08-08-2025
- Dividend Yield
- ISPC N/A
- REVB N/A
- EPS Growth
- ISPC N/A
- REVB N/A
- EPS
- ISPC N/A
- REVB N/A
- Revenue
- ISPC $8,058,631.00
- REVB N/A
- Revenue This Year
- ISPC $35.93
- REVB N/A
- Revenue Next Year
- ISPC N/A
- REVB N/A
- P/E Ratio
- ISPC N/A
- REVB N/A
- Revenue Growth
- ISPC N/A
- REVB N/A
- 52 Week Low
- ISPC $0.86
- REVB $0.74
- 52 Week High
- ISPC $11.80
- REVB $56.00
- Technical
- Relative Strength Index (RSI)
- ISPC 37.62
- REVB 26.64
- Support Level
- ISPC $0.86
- REVB $0.74
- Resistance Level
- ISPC $0.97
- REVB $0.88
- Average True Range (ATR)
- ISPC 0.06
- REVB 0.06
- MACD
- ISPC -0.02
- REVB 0.08
- Stochastic Oscillator
- ISPC 18.79
- REVB 32.49
About ISPC iSpecimen Inc.
iSpecimen Inc is a technology-driven company focused on connecting life science researchers who need human biofluids, solid tissues, and hematopoietic stem and immune cells for their research, with the available biospecimens. The company generates revenue by procuring various specimens from hospitals, laboratories, and other supply sites. Geographically, it has a presence in the Americas; Europe, the Middle East, Africa, and Asia Pacific, which majority, comes from the Americas.
About REVB Revelation Biosciences Inc.
Revelation Biosciences Inc is a clinical-stage life science company that is focused on rebalancing inflammation to optimize health using its proprietary formulation Gemini. It is developing a pipeline of potential high-value products based on Gemini. Gemini is Revelation's proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD) an established TLR4 agonist that can stimulate the human body's innate immune response to prevent and treat disease. The product candidates are developed are based on Gemini formulation of PHAD. Gemini-based programs consist of: Gemini-SSI developed for the prevention of surgical site infection (SSI); Gemini-AKI developed for the prevention of acute kidney injury (AKI); and Gemini-CKD for the treatment of chronic kidney disease (CKD).